Paul Van Schil

Prof. Dr. Paul Van Schil

Department of Thoracic and Vascular Surgery, Antwerp University and Antwerp University Hospital, Edegem, Belgium
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Radiology
Verified
Journal Article
Closed access
HMHeber MacMahon
Heber MacMahon
DNDavid P. Naidich
David P. Naidich
JGJin Mo Goo
Jin Mo Goo
KLKyung Soo Lee
Kyung Soo Lee
ALAnn N. C. Leung
Ann N. C. Leung
ABAlexander A. Bankier
Alexander A. Bankier
The minimum threshold size for routine follow-up has been increased, and recommended follow-up intervals are now given as a range rather than as a precise time period to give radiologists, clinicians, and patients greater discretion to accommodate individual risk factors and preferences. The Fleischner Society Guidelines for management of solid nodules were published in 2005, and separate guidelines for subsolid nodules were issued in 2013. Since then, new information has become available; therefore, the guidelines have been revised to reflect current thinking on nodule management. The revised guidelines incorporate several substantive changes that reflect current thinking on the management of small nodules. The minimum threshold size for routine follow-up has been increased, and recommended follow-up intervals are now given as a range rather than as a precise time period to give radiologists, clinicians, and patients greater discretion to accommodate individual risk factors and preferences. The guidelines for solid and subsolid nodules have been combined in one simplified table, and specific recommendations have been included for multiple nodules. These guidelines represent the consensus of the Fleischner Society, and as such, they incorporate the opinions of a multidisciplinary internat...

1 July 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
KCKari Chansky
Kari Chansky
FDFrank C. Detterbeck
Frank C. Detterbeck
ANAndrew G. Nicholson
Andrew G. Nicholson
VRValerie W. Rusch
Valerie W. Rusch
EVEric Vallières
Eric Vallières
KYK. Yokoi
K. Yokoi

1 December 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ADAnne-Marie C Dingemans
Anne-Marie C Dingemans
LHLizza E.L. Hendriks
Lizza E.L. Hendriks
TBThierry Berghmans
Thierry Berghmans
ALAntonin Levy
Antonin Levy
BHBaktiar Hasan
Baktiar Hasan
SNSilvia Novello
Silvia Novello

4 June 2010 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
PSPaul Van Schil
Paul Van Schil
PBP. Baas
P. Baas
RGR. Gaafar
R. Gaafar
AMA.P. Maat
A.P. Maat
MPM. Van de Pol
M. Van de Pol
JMJan P. van Meerbeeck
Jan P. van Meerbeeck
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less).Induction chemotherapy consisted of three courses of cisplatin 75 mg·m−2and pemetrexed 500 mg·m−2. Nonprogressing patients underwent extrapleural pneumonectomy followed by post-operative radiotherapy (54 Gy, 30 fractions). Our primary end-point was “success of treatment” and our secondary end-points were toxicity, and overall and progression-free survival.59 patients were registered, one of whom was ineligible. Subjects’ median age was 57 yrs. The subjects’ TNM scores were as follows: cT1, T2 and T3, 36, 16 and six patients, respectively; cN0 and N1, 57 and one patient, respectively. 55 (93%) patients received three cycles of chemotherapy with only mild toxicity. 46 (79%) patients received surgery and 42 (74%) had extrapleural pneumonectomy with a 90-day mortality of 6.5%. Post-operative radiotherapy was completed in 37 (65%) patients. Grade 3–4 toxicity persisted after 90 days in three (5.3%) patients. Median overall survival time was 18.4 months (95% CI 15.6–32.9) and median progression-free survival was 13.9 months (95% CI 10.9–17.2). Only 24 (42%) patients met the definition of success (one-sided 90% CI 0.36–1.00).Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary.

15 November 2017 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
ASAnnemie Snoeckx
Annemie Snoeckx
PRPieter Reyntiens
Pieter Reyntiens
DDDamien Desbuquoit
Damien Desbuquoit
MSMaarten J. Spinhoven
Maarten J. Spinhoven
PSPaul Van Schil
Paul Van Schil
PPPaul Maria R. Parizel
Paul Maria R. Parizel
Subsequent to the widespread use of multidetector computed tomography and growing interest in lung cancer screening, small pulmonary nodules are more frequently detected. The differential diagnosis for a solitary pulmonary nodule is extremely broad and includes both benign and malignant causes. Recognition of early lung cancers is vital, since stage at diagnosis is crucial for prognosis. Estimation of the probability of malignancy is a challenging task, but crucial for follow-up and further work-up. In addition to the clinical setting and metabolic assessment, morphological assessment on thin-section computed tomography is essential. Size and growth are key factors in assessment of the malignant potential of a nodule. The likelihood of malignancy positively correlates with nodule diameter: as the diameter increases, so does the likelihood of malignancy. Although there is a considerable overlap in the features of benign and malignant nodules, the importance of morphology however should not be underestimated. Features that are associated with benignity include a perifissural location and triangular morphology, internal fat and benign calcifications. Malignancy is suspected in nodules presenting with spiculation, lobulation, pleural indentation, vascular convergence sign, associated cystic airspace, bubble-like lucencies, irregular air bronchogram, and subsolid morphology. Nodules often show different features and combination of findings is certainly more powerful. Teaching points • Size of a pulmonary nodule is important, but morphological assessment should not be underestimated. • Lung nodules should be evaluated on thin section CT, in both lung and mediastinal window setting. • Features associated with benignity include a triangular morphology, internal fat and calcifications. • Spiculation, pleural retraction and notch sign are highly suggestive of a malignant nature. • Complex features (e.g. bubble-like lucencies) are highly indicative of a malignant nature.

1 March 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JEJohn G Edwards
John G Edwards
KCKari Chansky
Kari Chansky
PSPaul Van Schil
Paul Van Schil
ANAndrew G Nicholson
Andrew G Nicholson
SBSouheil Boubia
Souheil Boubia
IIInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions
International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions